Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Tarsus Pharmaceuticals (TARS) Other Gross PP&E Adjustments (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 6 years of Other Gross PP&E Adjustments data on record, last reported at -$3.2 million in Q4 2025.

  • For Q4 2025, Other Gross PP&E Adjustments fell 212.52% year-over-year to -$3.2 million; the TTM value through Dec 2025 reached -$3.2 million, down 212.52%, while the annual FY2025 figure was -$3.2 million, 212.52% down from the prior year.
  • Other Gross PP&E Adjustments reached -$3.2 million in Q4 2025 per TARS's latest filing, down from -$2.1 million in the prior quarter.
  • Across five years, Other Gross PP&E Adjustments topped out at $4.9 million in Q2 2025 and bottomed at -$3.2 million in Q4 2025.
  • Average Other Gross PP&E Adjustments over 5 years is $286350.0, with a median of $243500.0 recorded in 2022.
  • Peak YoY movement for Other Gross PP&E Adjustments: tumbled 1226.88% in 2021, then skyrocketed 692.37% in 2024.
  • A 5-year view of Other Gross PP&E Adjustments shows it stood at -$1.2 million in 2021, then grew by 3.48% to -$1.2 million in 2022, then tumbled by 140.89% to -$2.9 million in 2023, then soared by 64.38% to -$1.0 million in 2024, then crashed by 212.52% to -$3.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Gross PP&E Adjustments were -$3.2 million in Q4 2025, -$2.1 million in Q3 2025, and $4.9 million in Q2 2025.